Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Centre for Primary Care and Public Health, Blizard Institute, Queen Mary University of London, London, UK.
Diabetes Obes Metab. 2019 Nov;21(11):2405-2412. doi: 10.1111/dom.13821. Epub 2019 Jul 21.
In England and Wales, the National Diabetes Audit (NDA) assesses the quality of management of type 2 diabetes (T2D) in primary care using treatment targets for HbA1c ≤58 mmol/mol, total cholesterol <5 mmol/L and blood pressure ≤140/80 mm Hg. We quantified the impact of variation in achieving these targets on health outcomes and healthcare costs across general practitioners' (GP) practices.
Summary of characteristics of T2D patients from the 2015-2016 NDA were used to generate representative populations of T2D patients. The UKPDS Outcomes Model 2 was used to estimate long-term health outcomes and healthcare costs. The effects of achieving treatment targets on these outcomes were evaluated using regression models.
Achieving more of the HbA1c, cholesterol and blood pressure targets led to a lower incidence of diabetes-related complications. Approximately 0.5 (95% CI, 0.4-0.6) quality-adjusted life years (QALYs) and 0.6 (95% CI, 0.4-0.7) years of life (LYs) were gained by T2D patients over a lifetime for each additional target met. The projected healthcare cost savings arising from fewer diabetes-related complications as the result of achieving one, two or three targets compared to none were £859 (95% CI, £553-£1165), £940 (95% CI, £485-£1395) and £1037 (95% CI, £414-£1660) over a patient's lifetime. A typical GP practice in the lowest performing decile (average, 371 T2D patients per practice, with 27% achieving all targets) is projected to gain 201 (95% CI, 123-279) QALYs and 231 (95% CI, 133-329) LYs, if all T2D patients achieved all three targets.
Substantial gains in health outcomes and reductions in healthcare costs could be achieved with further improvements in attainment of HbA1c, cholesterol and blood pressure targets for T2D patients.
在英格兰和威尔士,国家糖尿病审计(NDA)使用糖化血红蛋白≤58mmol/mol、总胆固醇<5mmol/L 和血压≤140/80mmHg 的治疗目标,评估基层医疗中 2 型糖尿病(T2D)的管理质量。我们量化了在全科医生(GP)实践中实现这些目标的差异对健康结果和医疗保健成本的影响。
使用 2015-2016 年 NDA 中 T2D 患者特征的总结数据生成具有代表性的 T2D 患者人群。使用 UKPDS 结果模型 2 估计长期健康结果和医疗保健成本。使用回归模型评估实现治疗目标对这些结果的影响。
实现更多的糖化血红蛋白、胆固醇和血压目标可降低糖尿病相关并发症的发生率。在一生中,T2D 患者每多达到一个目标,就会获得大约 0.5(95%CI,0.4-0.6)个质量调整生命年(QALY)和 0.6(95%CI,0.4-0.7)年的生命(LY)。与没有达到任何目标相比,由于实现一个、两个或三个目标而减少糖尿病相关并发症所带来的预计医疗保健成本节约分别为 859 英镑(95%CI,553-1165 英镑)、940 英镑(95%CI,485-1395 英镑)和 1037 英镑(95%CI,414-1660 英镑)。在患者的一生中,一个表现最差的十分位数(平均每个 GP 实践有 371 名 T2D 患者,只有 27%的患者达到所有目标)预计将获得 201(95%CI,123-279)个 QALY 和 231(95%CI,133-329)个 LY,如果所有 T2D 患者都达到了所有三个目标。
如果进一步提高 T2D 患者的糖化血红蛋白、胆固醇和血压目标达标率,可显著提高健康结果,并降低医疗保健成本。